Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis

Familial Cancer

Volumn 15, Issue 2, 2016, Pages 221-230

  Lan, Zhu ^a   Fu, Dan ^b   Yu, Xiuzhang ^a   Xi, Mingrong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cancer antigen 125; Diagnosis; Osteopontin; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; OSTEOPONTIN; TUMOR MARKER; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

AREA UNDER THE CURVE; CANCER DIAGNOSIS; CHINESE BIOMEDICAL DATABASE; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EMBASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEDLINE; META ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; BLOOD; FEMALE; OVARIAN NEOPLASMS;

BIOMARKERS, TUMOR; CA-125 ANTIGEN; FEMALE; HUMANS; MEMBRANE PROTEINS; OSTEOPONTIN; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84944602922     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-015-9847-3     Document Type: Review

References (47)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236
2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin. 64:9–29
3. American Cancer Society (2014) Cancer facts and figures 2014. American Cancer Society, Atlanta
4. Zhen S, Bian LH, Chang LL, Gao X (2014) Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: a meta-analysis. Mol Clin Oncol 2(4):559–566
5. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374(9698):1371–1382
6. Baldwin LA, Huang B, Miller RW et al (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120:612–618
7. Li F, Tie R, Chang K et al (2012) Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer 12:258
8. Bast RC Jr, Badgwell D, Lu Z et al (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(Suppl 3):274–281
9. Niloff JM, Klug TL, Schaetzl E et al (1984) Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148:1057–1058
10. Yurkovetsky Z, Skates S, Lomakin A et al (2010) Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28:2159–2166
11. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2011) Pre-and post-translational regulation of osteopontin in cancer. J. Cell Commun Signal 5:111
12. Fedarko NS, Jain A, Karadag A et al (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7(12):4060–4066
13. Koopmann J, Fedarko NS, Jain A et al (2004) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomark Prev 13(3):487–491
14. Wong KK, Cheng RS, Mok SC (2001) Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30:670–675
15. Matsuura M, Suzuki T, Saito T (2007) Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci (in press)
16. Bao L, Sakaguchi H, Fujimoto J et al (2007) Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 14:373–381
17. Kim JH, Skates SJ, Uede T et al (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13):1671–1679
18. Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536
19. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
20. Li MJ, Yang YQ, Peng CX et al (2013) Significance of OPN combined with CA125 in early diagnosis of ovarian cancer. Prog Mod Biomed 13(04):691–693
21. Zhao YH, Zhang Q, Hao F (2012) The diagnostic values of combined determination of serum tumor markers HE4, OPN and CA125 levels in patients with epithelial ovarian cancer. J Med Theor Pract 25(23):2283–2285
22. Fan JB, Zhang GL, Wu J et al (2012) Clinical value of b-type ultrasonography combined with serum levels of OPN and CA125 in the early diagnosis of ovarian cancer. J Shanxi Med Univ 43(03):225–228
23. Yang B, Jia J, Shi DM, Li J, Chen I (2012) Evaluation of selected serum proteins CA125 and OPN as diagnosis of ovarian cancer. Prog Mod Biomed 12(9):1742–1744
24. Yang JH, Liu JH, Shun ZP (2007) Detection of osteopontin and CA125 in patients with ovarian cancer and its clinical significance. Chin J Fam Plan 139(5):303–305
25. Wu FJ, Guan S, Huang BY et al (2009) Detection of osteopontin and CA125 in patients with ovarian cancer and its clinical significance. Chin J Lab Diagn. 13(9):1170–1172
26. Zhou YH, Wu XF (2008) Significance of OPN combined with CA125 in diagnosis of epithelial ovarian cancer. J Clin Exp Med 07(04):35–37
27. Zhang YJ, Yuan ZF (2013) Expression and significance ofHE4, OPN and c-OPN in carcinoma, ascites, serum and urine in patients with epithelial ovarian cancer. Matern Child Healthc China 28(14):2290–2293
28. Wang Y, Wang J, Zhang ZM et al (2013) Clinical significance of serum OPN, HE4 and CA125 levels in patients with ovarian cancer. Prog Mod Biomed 13(30):5937–5940
29. Mor G, Visintin I, Lai Y et al (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102:7677–7682
30. Nakae M, Iwamoto I, Fujino T et al (2006) Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 32(3):309–314
31. Meinhold-Heerlein I, Bauerschlag D, Zhou Y et al (2007) An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 13:458–466
32. Moore RG, Brown AK, Miller MC et al (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108:402–408
33. Bandiera E, Zanotti L, Fabricio AS et al (2013) Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 51:1815–1824
34. Moszynski R, Szubert S, Szpurek D, Michalak S, Sajdak S (2013) Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res 39(11):1518–1525
35. Milivojevic M, Boskovic V, Atanackovic J et al (2013) Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma. Eur J Gynaecol Oncol 34:83–85
36. Yan Y, Liu Z, Liu DQ et al (2013) Combination of serum CA125, HE4 and OPN in the diagnosis of ovarian cancer. Chin J Clin Med 20(04):440–442
37. Zamora J, Abraira V, Muriel A et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31
38. Wang YD, Chen H, Liu HQ, Hao M (2014) Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis. Tumour Biol 35(12):11799–11808
39. Jaeschke R, Guyatt G, Lijmer J (2002) Diagnostic tests. In: Guyatt G, Rennie D (eds) Users guides to the medical literature: a manual for evidence-based clinical practice. AMA Press, Chicago, pp 121–140
40. Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM (2010) Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 104(1):149–156
41. Medeiros LR, Rosa DD, da Rosa MI et al (2009) Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 142(2):99–105
42. Visintin I, Feng Z, Longton G et al (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14:1065–1072
43. Vrzalova J, Prazakova M, Novotny Z et al (2009) Test of ovarian cancer multiplex xMAP technology panel. Anticancer Res 29:573–576
44. Lu D, Kuhn E, Bristow RE et al (2011) Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 122:560–566
45. He G, Holcroft CA, Beauchamp MC et al (2012) Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. J Obstet Gynaecol Cancer 34:567–574
46. Fredriksson S, Horecka J, Brustugun OT et al (2008) Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem 54:582–589
47. de Groot JA, Bossuyt PM, Reitsma JB et al (2011) Verification problems in diagnostic accuracy studies: consequences and solutions. BMJ 343:d4770. doi:10.1136/bmj.d4770